chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 63.0
Sex: M
Vaccine: YF, YF
Symptoms: Alanine aminotransferase increased, Aspartate aminotransferase increased, Blood alkaline phosphatase increased, Blood bilirubin increased, Cytomegalovirus colitis
Clinical narrative: Initial report was received 12 may 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 308850. A 63-year-old male patient with a history of Crohn's disease had received an injection of Yellow Fever Vaccine (lot number, route and site of administration not reported) on 18 January 2008. The patient traveled from 29 January 2008 to February 20 200. While he was traveling, there was a large outbreak of Dengue fever in the area where he was. He experienced onset of severe headache, photophobia and nausea which began 19 February 2008. He had intermittent episodes of fever with profuse sweating which began 21 February 2008. He was hospitalized on 02 March 2008 and discharged on 19 March 2008 with a principle discharge diagnosis of fever, CMV colitis and candidas of esophagus. The patient had a history of Crohn's disease and had last been on steroids one year prior to the event. A small volume of serum was received at the CDC however due to limited sample size, only PRNT for yellow fever antibodies could be performed with a result of 1:80 titer. The event was classified as "possible YF vaccine associated viscerotropic illness". The patient's recovery status was not reported and no further information was provided.
Age: 63.0
Sex: M
Vaccine: YF, YF
Symptoms: Exposure to communicable disease, Headache, Hyperhidrosis, Nausea, Oesophageal candidiasis
Clinical narrative: Initial report was received 12 may 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 308850. A 63-year-old male patient with a history of Crohn's disease had received an injection of Yellow Fever Vaccine (lot number, route and site of administration not reported) on 18 January 2008. The patient traveled from 29 January 2008 to February 20 200. While he was traveling, there was a large outbreak of Dengue fever in the area where he was. He experienced onset of severe headache, photophobia and nausea which began 19 February 2008. He had intermittent episodes of fever with profuse sweating which began 21 February 2008. He was hospitalized on 02 March 2008 and discharged on 19 March 2008 with a principle discharge diagnosis of fever, CMV colitis and candidas of esophagus. The patient had a history of Crohn's disease and had last been on steroids one year prior to the event. A small volume of serum was received at the CDC however due to limited sample size, only PRNT for yellow fever antibodies could be performed with a result of 1:80 titer. The event was classified as "possible YF vaccine associated viscerotropic illness". The patient's recovery status was not reported and no further information was provided.
Age: 63.0
Sex: M
Vaccine: YF, YF
Symptoms: Photophobia, Pyrexia
Clinical narrative: Initial report was received 12 may 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 308850. A 63-year-old male patient with a history of Crohn's disease had received an injection of Yellow Fever Vaccine (lot number, route and site of administration not reported) on 18 January 2008. The patient traveled from 29 January 2008 to February 20 200. While he was traveling, there was a large outbreak of Dengue fever in the area where he was. He experienced onset of severe headache, photophobia and nausea which began 19 February 2008. He had intermittent episodes of fever with profuse sweating which began 21 February 2008. He was hospitalized on 02 March 2008 and discharged on 19 March 2008 with a principle discharge diagnosis of fever, CMV colitis and candidas of esophagus. The patient had a history of Crohn's disease and had last been on steroids one year prior to the event. A small volume of serum was received at the CDC however due to limited sample size, only PRNT for yellow fever antibodies could be performed with a result of 1:80 titer. The event was classified as "possible YF vaccine associated viscerotropic illness". The patient's recovery status was not reported and no further information was provided.
Age: 63.0
Sex: M
Vaccine: YF, YF
Symptoms: Antibody test positive, Cytomegalovirus colitis, Headache, Hyperhidrosis, Nausea
Clinical narrative: Initial report was received 12 may 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 308850. A 63-year-old male patient with a history of Crohn's disease had received an injection of Yellow Fever Vaccine (lot number, route and site of administration not reported) on 18 January 2008. The patient traveled from 29 January 2008 to February 20 200. While he was traveling, there was a large outbreak of Dengue fever in the area where he was. He experienced onset of severe headache, photophobia and nausea which began 19 February 2008. He had intermittent episodes of fever with profuse sweating which began 21 February 2008. He was hospitalized on 02 March 2008 and discharged on 19 March 2008 with a principle discharge diagnosis of fever, CMV colitis and candidas of esophagus. The patient had a history of Crohn's disease and had last been on steroids one year prior to the event. A small volume of serum was received at the CDC however due to limited sample size, only PRNT for yellow fever antibodies could be performed with a result of 1:80 titer. The event was classified as "possible YF vaccine associated viscerotropic illness". The patient's recovery status was not reported and no further information was provided.
Age: 63.0
Sex: M
Vaccine: YF, YF
Symptoms: Oesophageal candidiasis, Photophobia, Pyrexia
Clinical narrative: Initial report was received 12 may 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 308850. A 63-year-old male patient with a history of Crohn's disease had received an injection of Yellow Fever Vaccine (lot number, route and site of administration not reported) on 18 January 2008. The patient traveled from 29 January 2008 to February 20 200. While he was traveling, there was a large outbreak of Dengue fever in the area where he was. He experienced onset of severe headache, photophobia and nausea which began 19 February 2008. He had intermittent episodes of fever with profuse sweating which began 21 February 2008. He was hospitalized on 02 March 2008 and discharged on 19 March 2008 with a principle discharge diagnosis of fever, CMV colitis and candidas of esophagus. The patient had a history of Crohn's disease and had last been on steroids one year prior to the event. A small volume of serum was received at the CDC however due to limited sample size, only PRNT for yellow fever antibodies could be performed with a result of 1:80 titer. The event was classified as "possible YF vaccine associated viscerotropic illness". The patient's recovery status was not reported and no further information was provided.
Age: 69.0
Sex: F
Vaccine: HEP, TD, YF, YF
Symptoms: Activities of daily living impaired, Arthralgia, Asthenia, Back pain, Confusional state
Clinical narrative: Initial report was received 12 May 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 310050. A 69-year-old female patient had received a first dose injection of YF VAX on 09 March 2006 and approximately 14 days later on 23 March 2006, while on a cruise, she developed acute febrile illness with fevers up to 105 degrees Fahrenheit, confusion and generalized malaise. The patient was hospitalized for five days and then transferred to ah hospital and then subsequently transferred to a rehabilitation unit. The patient stated that she never returned to normal. The patient had symptoms of urinary incontinence, persistent profound fatigue, myalgias, arthralgias, low back pain, frequent headaches, and occasional falls with leg weakness. She had been evaluated by a neurologist who found a scratch from a sloth prior to the febrile illness and referred her to an infectious disease specialist to follow-up on that finding. The infectious disease specialist ordered serology testing for St. Louis encephalitis, eastern equine encephalitis and HTLV-1 which were all negative. There was no remaining CSF at the hospital for additional testing at CDC.
Age: 69.0
Sex: F
Vaccine: HEP, TD, YF, YF
Symptoms: Fall, Fatigue, Febrile infection, Headache, Malaise
Clinical narrative: Initial report was received 12 May 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 310050. A 69-year-old female patient had received a first dose injection of YF VAX on 09 March 2006 and approximately 14 days later on 23 March 2006, while on a cruise, she developed acute febrile illness with fevers up to 105 degrees Fahrenheit, confusion and generalized malaise. The patient was hospitalized for five days and then transferred to ah hospital and then subsequently transferred to a rehabilitation unit. The patient stated that she never returned to normal. The patient had symptoms of urinary incontinence, persistent profound fatigue, myalgias, arthralgias, low back pain, frequent headaches, and occasional falls with leg weakness. She had been evaluated by a neurologist who found a scratch from a sloth prior to the febrile illness and referred her to an infectious disease specialist to follow-up on that finding. The infectious disease specialist ordered serology testing for St. Louis encephalitis, eastern equine encephalitis and HTLV-1 which were all negative. There was no remaining CSF at the hospital for additional testing at CDC.
Age: 69.0
Sex: F
Vaccine: HEP, TD, YF, YF
Symptoms: Muscular weakness, Myalgia, Pyrexia, Somnolence, Thinking abnormal
Clinical narrative: Initial report was received 12 May 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 310050. A 69-year-old female patient had received a first dose injection of YF VAX on 09 March 2006 and approximately 14 days later on 23 March 2006, while on a cruise, she developed acute febrile illness with fevers up to 105 degrees Fahrenheit, confusion and generalized malaise. The patient was hospitalized for five days and then transferred to ah hospital and then subsequently transferred to a rehabilitation unit. The patient stated that she never returned to normal. The patient had symptoms of urinary incontinence, persistent profound fatigue, myalgias, arthralgias, low back pain, frequent headaches, and occasional falls with leg weakness. She had been evaluated by a neurologist who found a scratch from a sloth prior to the febrile illness and referred her to an infectious disease specialist to follow-up on that finding. The infectious disease specialist ordered serology testing for St. Louis encephalitis, eastern equine encephalitis and HTLV-1 which were all negative. There was no remaining CSF at the hospital for additional testing at CDC.
Age: 69.0
Sex: F
Vaccine: HEP, TD, YF, YF
Symptoms: Urinary incontinence
Clinical narrative: Initial report was received 12 May 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 310050. A 69-year-old female patient had received a first dose injection of YF VAX on 09 March 2006 and approximately 14 days later on 23 March 2006, while on a cruise, she developed acute febrile illness with fevers up to 105 degrees Fahrenheit, confusion and generalized malaise. The patient was hospitalized for five days and then transferred to ah hospital and then subsequently transferred to a rehabilitation unit. The patient stated that she never returned to normal. The patient had symptoms of urinary incontinence, persistent profound fatigue, myalgias, arthralgias, low back pain, frequent headaches, and occasional falls with leg weakness. She had been evaluated by a neurologist who found a scratch from a sloth prior to the febrile illness and referred her to an infectious disease specialist to follow-up on that finding. The infectious disease specialist ordered serology testing for St. Louis encephalitis, eastern equine encephalitis and HTLV-1 which were all negative. There was no remaining CSF at the hospital for additional testing at CDC.
Age: 69.0
Sex: F
Vaccine: HEP, TD, YF, YF
Symptoms: Arthralgia, Back pain, Confusional state, Fall, Fatigue
Clinical narrative: Initial report was received 12 May 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 310050. A 69-year-old female patient had received a first dose injection of YF VAX on 09 March 2006 and approximately 14 days later on 23 March 2006, while on a cruise, she developed acute febrile illness with fevers up to 105 degrees Fahrenheit, confusion and generalized malaise. The patient was hospitalized for five days and then transferred to ah hospital and then subsequently transferred to a rehabilitation unit. The patient stated that she never returned to normal. The patient had symptoms of urinary incontinence, persistent profound fatigue, myalgias, arthralgias, low back pain, frequent headaches, and occasional falls with leg weakness. She had been evaluated by a neurologist who found a scratch from a sloth prior to the febrile illness and referred her to an infectious disease specialist to follow-up on that finding. The infectious disease specialist ordered serology testing for St. Louis encephalitis, eastern equine encephalitis and HTLV-1 which were all negative. There was no remaining CSF at the hospital for additional testing at CDC.
Age: 69.0
Sex: F
Vaccine: HEP, TD, YF, YF
Symptoms: Headache, Malaise, Muscular weakness, Myalgia, Pyrexia
Clinical narrative: Initial report was received 12 May 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 310050. A 69-year-old female patient had received a first dose injection of YF VAX on 09 March 2006 and approximately 14 days later on 23 March 2006, while on a cruise, she developed acute febrile illness with fevers up to 105 degrees Fahrenheit, confusion and generalized malaise. The patient was hospitalized for five days and then transferred to ah hospital and then subsequently transferred to a rehabilitation unit. The patient stated that she never returned to normal. The patient had symptoms of urinary incontinence, persistent profound fatigue, myalgias, arthralgias, low back pain, frequent headaches, and occasional falls with leg weakness. She had been evaluated by a neurologist who found a scratch from a sloth prior to the febrile illness and referred her to an infectious disease specialist to follow-up on that finding. The infectious disease specialist ordered serology testing for St. Louis encephalitis, eastern equine encephalitis and HTLV-1 which were all negative. There was no remaining CSF at the hospital for additional testing at CDC.
Age: 69.0
Sex: F
Vaccine: HEP, TD, YF, YF
Symptoms: Serology negative, Urinary incontinence, Virus serology test positive
Clinical narrative: Initial report was received 12 May 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 310050. A 69-year-old female patient had received a first dose injection of YF VAX on 09 March 2006 and approximately 14 days later on 23 March 2006, while on a cruise, she developed acute febrile illness with fevers up to 105 degrees Fahrenheit, confusion and generalized malaise. The patient was hospitalized for five days and then transferred to ah hospital and then subsequently transferred to a rehabilitation unit. The patient stated that she never returned to normal. The patient had symptoms of urinary incontinence, persistent profound fatigue, myalgias, arthralgias, low back pain, frequent headaches, and occasional falls with leg weakness. She had been evaluated by a neurologist who found a scratch from a sloth prior to the febrile illness and referred her to an infectious disease specialist to follow-up on that finding. The infectious disease specialist ordered serology testing for St. Louis encephalitis, eastern equine encephalitis and HTLV-1 which were all negative. There was no remaining CSF at the hospital for additional testing at CDC.
Age: 88.0
Sex: F
Vaccine: YF, YF
Symptoms: Diarrhoea, Nausea, Renal failure
Clinical narrative: Initial report was received 12 May 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 310051. An 88-year-old female patient received YF VAX (date, route, site and dose number of vaccination not reported). On 10 April 2008, the patient developed nausea and diarrhea. The patient was admitted to the hospital on 18 April 2008 for possible renal failure. The patient received a Cat Scan (date not provided) and the results indicated a gallbladder infection. The patient underwent surgery and was awaiting additional information. No further information was provided at the time of the report.
Age: 88.0
Sex: F
Vaccine: YF, YF
Symptoms: Cholecystitis infective, Computerised tomogram abnormal, Diarrhoea, Nausea, Surgery
Clinical narrative: Initial report was received 12 May 2008 from the Centers for Disease Control and Prevention and the members of the Yellow Fever Working Group in reference to VAERS ID# 310051. An 88-year-old female patient received YF VAX (date, route, site and dose number of vaccination not reported). On 10 April 2008, the patient developed nausea and diarrhea. The patient was admitted to the hospital on 18 April 2008 for possible renal failure. The patient received a Cat Scan (date not provided) and the results indicated a gallbladder infection. The patient underwent surgery and was awaiting additional information. No further information was provided at the time of the report.
Age: 42.0
Sex: F
Vaccine: YF, YF
Symptoms: Alanine aminotransferase increased, Aspartate aminotransferase increased, Bilirubin conjugated, Blood bilirubin unconjugated, Blood chloride normal
Clinical narrative: A 42-year-old female received a right arm injection of YF-Vax (lot number not provided) on 25 March 2008. The patient was on foreign travel, and was on a ship at the time of vaccination; she was in her usual state of health the day prior to vaccination. Approximately one hour after administration, she began experiencing erythema and pruritus around the injection site, affecting the right arm. Symptoms persisted for ten days. Approximately ten days after vaccination, the patient developed headache, fevers to 103 degrees, chills, drenching sweats, and myalgias. A short time later she developed bilateral axillary lymphadenopathy and plaques, described as slightly raised, scattered, circumscribed, erythematous and non-scaling. The area was tender to palpation, and affected only bilateral lower extremities. No complaints of cough, nausea, vomiting, or abdominal pain were noted. She was treated for a presumed unspecified infection with azithromycin and indomethacin, and as of 21 April 2008 her symptoms were improving. It did not appear that a lumbar puncture had been performed
Age: 42.0
Sex: F
Vaccine: YF, YF
Symptoms: Blood lactate dehydrogenase increased, Blood potassium normal, Blood sodium normal, Chest X-ray abnormal, Chills
Clinical narrative: A 42-year-old female received a right arm injection of YF-Vax (lot number not provided) on 25 March 2008. The patient was on foreign travel, and was on a ship at the time of vaccination; she was in her usual state of health the day prior to vaccination. Approximately one hour after administration, she began experiencing erythema and pruritus around the injection site, affecting the right arm. Symptoms persisted for ten days. Approximately ten days after vaccination, the patient developed headache, fevers to 103 degrees, chills, drenching sweats, and myalgias. A short time later she developed bilateral axillary lymphadenopathy and plaques, described as slightly raised, scattered, circumscribed, erythematous and non-scaling. The area was tender to palpation, and affected only bilateral lower extremities. No complaints of cough, nausea, vomiting, or abdominal pain were noted. She was treated for a presumed unspecified infection with azithromycin and indomethacin, and as of 21 April 2008 her symptoms were improving. It did not appear that a lumbar puncture had been performed
Age: 42.0
Sex: F
Vaccine: YF, YF
Symptoms: Haematocrit decreased, Haemoglobin decreased, Headache, Hyperhidrosis, Infection
Clinical narrative: A 42-year-old female received a right arm injection of YF-Vax (lot number not provided) on 25 March 2008. The patient was on foreign travel, and was on a ship at the time of vaccination; she was in her usual state of health the day prior to vaccination. Approximately one hour after administration, she began experiencing erythema and pruritus around the injection site, affecting the right arm. Symptoms persisted for ten days. Approximately ten days after vaccination, the patient developed headache, fevers to 103 degrees, chills, drenching sweats, and myalgias. A short time later she developed bilateral axillary lymphadenopathy and plaques, described as slightly raised, scattered, circumscribed, erythematous and non-scaling. The area was tender to palpation, and affected only bilateral lower extremities. No complaints of cough, nausea, vomiting, or abdominal pain were noted. She was treated for a presumed unspecified infection with azithromycin and indomethacin, and as of 21 April 2008 her symptoms were improving. It did not appear that a lumbar puncture had been performed
Age: 42.0
Sex: F
Vaccine: YF, YF
Symptoms: Injection site erythema, Injection site pruritus, Lymphadenopathy, Mean cell volume abnormal, Myalgia
Clinical narrative: A 42-year-old female received a right arm injection of YF-Vax (lot number not provided) on 25 March 2008. The patient was on foreign travel, and was on a ship at the time of vaccination; she was in her usual state of health the day prior to vaccination. Approximately one hour after administration, she began experiencing erythema and pruritus around the injection site, affecting the right arm. Symptoms persisted for ten days. Approximately ten days after vaccination, the patient developed headache, fevers to 103 degrees, chills, drenching sweats, and myalgias. A short time later she developed bilateral axillary lymphadenopathy and plaques, described as slightly raised, scattered, circumscribed, erythematous and non-scaling. The area was tender to palpation, and affected only bilateral lower extremities. No complaints of cough, nausea, vomiting, or abdominal pain were noted. She was treated for a presumed unspecified infection with azithromycin and indomethacin, and as of 21 April 2008 her symptoms were improving. It did not appear that a lumbar puncture had been performed
Age: 42.0
Sex: F
Vaccine: YF, YF
Symptoms: Platelet count increased, Pyrexia, Red blood cell sedimentation rate increased, Red cell distribution width increased, Skin plaque
Clinical narrative: A 42-year-old female received a right arm injection of YF-Vax (lot number not provided) on 25 March 2008. The patient was on foreign travel, and was on a ship at the time of vaccination; she was in her usual state of health the day prior to vaccination. Approximately one hour after administration, she began experiencing erythema and pruritus around the injection site, affecting the right arm. Symptoms persisted for ten days. Approximately ten days after vaccination, the patient developed headache, fevers to 103 degrees, chills, drenching sweats, and myalgias. A short time later she developed bilateral axillary lymphadenopathy and plaques, described as slightly raised, scattered, circumscribed, erythematous and non-scaling. The area was tender to palpation, and affected only bilateral lower extremities. No complaints of cough, nausea, vomiting, or abdominal pain were noted. She was treated for a presumed unspecified infection with azithromycin and indomethacin, and as of 21 April 2008 her symptoms were improving. It did not appear that a lumbar puncture had been performed
Age: 42.0
Sex: F
Vaccine: YF, YF
Symptoms: Smear site unspecified abnormal, Tenderness, White blood cell count
Clinical narrative: A 42-year-old female received a right arm injection of YF-Vax (lot number not provided) on 25 March 2008. The patient was on foreign travel, and was on a ship at the time of vaccination; she was in her usual state of health the day prior to vaccination. Approximately one hour after administration, she began experiencing erythema and pruritus around the injection site, affecting the right arm. Symptoms persisted for ten days. Approximately ten days after vaccination, the patient developed headache, fevers to 103 degrees, chills, drenching sweats, and myalgias. A short time later she developed bilateral axillary lymphadenopathy and plaques, described as slightly raised, scattered, circumscribed, erythematous and non-scaling. The area was tender to palpation, and affected only bilateral lower extremities. No complaints of cough, nausea, vomiting, or abdominal pain were noted. She was treated for a presumed unspecified infection with azithromycin and indomethacin, and as of 21 April 2008 her symptoms were improving. It did not appear that a lumbar puncture had been performed
Age: 42.0
Sex: F
Vaccine: YF, YF
Symptoms: Chills, Headache, Hyperhidrosis, Injection site erythema, Injection site pruritus
Clinical narrative: A 42-year-old female received a right arm injection of YF-Vax (lot number not provided) on 25 March 2008. The patient was on foreign travel, and was on a ship at the time of vaccination; she was in her usual state of health the day prior to vaccination. Approximately one hour after administration, she began experiencing erythema and pruritus around the injection site, affecting the right arm. Symptoms persisted for ten days. Approximately ten days after vaccination, the patient developed headache, fevers to 103 degrees, chills, drenching sweats, and myalgias. A short time later she developed bilateral axillary lymphadenopathy and plaques, described as slightly raised, scattered, circumscribed, erythematous and non-scaling. The area was tender to palpation, and affected only bilateral lower extremities. No complaints of cough, nausea, vomiting, or abdominal pain were noted. She was treated for a presumed unspecified infection with azithromycin and indomethacin, and as of 21 April 2008 her symptoms were improving. It did not appear that a lumbar puncture had been performed
Age: 42.0
Sex: F
Vaccine: YF, YF
Symptoms: Lymphadenopathy, Myalgia, Oropharyngeal plaque, Pyrexia, Skin plaque
Clinical narrative: A 42-year-old female received a right arm injection of YF-Vax (lot number not provided) on 25 March 2008. The patient was on foreign travel, and was on a ship at the time of vaccination; she was in her usual state of health the day prior to vaccination. Approximately one hour after administration, she began experiencing erythema and pruritus around the injection site, affecting the right arm. Symptoms persisted for ten days. Approximately ten days after vaccination, the patient developed headache, fevers to 103 degrees, chills, drenching sweats, and myalgias. A short time later she developed bilateral axillary lymphadenopathy and plaques, described as slightly raised, scattered, circumscribed, erythematous and non-scaling. The area was tender to palpation, and affected only bilateral lower extremities. No complaints of cough, nausea, vomiting, or abdominal pain were noted. She was treated for a presumed unspecified infection with azithromycin and indomethacin, and as of 21 April 2008 her symptoms were improving. It did not appear that a lumbar puncture had been performed
Age: 42.0
Sex: F
Vaccine: YF, YF
Symptoms: Tenderness
Clinical narrative: A 42-year-old female received a right arm injection of YF-Vax (lot number not provided) on 25 March 2008. The patient was on foreign travel, and was on a ship at the time of vaccination; she was in her usual state of health the day prior to vaccination. Approximately one hour after administration, she began experiencing erythema and pruritus around the injection site, affecting the right arm. Symptoms persisted for ten days. Approximately ten days after vaccination, the patient developed headache, fevers to 103 degrees, chills, drenching sweats, and myalgias. A short time later she developed bilateral axillary lymphadenopathy and plaques, described as slightly raised, scattered, circumscribed, erythematous and non-scaling. The area was tender to palpation, and affected only bilateral lower extremities. No complaints of cough, nausea, vomiting, or abdominal pain were noted. She was treated for a presumed unspecified infection with azithromycin and indomethacin, and as of 21 April 2008 her symptoms were improving. It did not appear that a lumbar puncture had been performed
Age: 0.2
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5
Symptoms: Petechiae, Platelet count decreased
Clinical narrative: Information regarding PREVENAR was received from a healthcare professional regarding a 2-month-old female patient who experienced petechiae and spontaneous ecchymosis. The patient received the first dose on 16-May-2008. The patient also received the first dose of ROTATEQ and the first dose of PEDIARIX (GlaxoSmithKline) on 16-May-2008. Relevant medical history was not provided. Additional suspect vaccines included ROTATEQ, PEDIARIX and ACT-HIB. On 16-May-2008, the patient experienced petechiae and spontaneous ecchymosis and was hospitalized. Laboratory tests were performed (see laboratory results) as sepsis was suspected. No sepsis was found. The patient was hospitalized for 3 days and was discharged and considered recovered. The patient's discharge diagnosis was spontaneous ecchymosis. No additional information was available at the time of this report.
Age: 0.2
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5
Symptoms: Activated partial thromboplastin time normal, Blood culture negative, CSF culture negative, Coombs indirect test negative, Culture urine negative
Clinical narrative: Information regarding PREVENAR was received from a healthcare professional regarding a 2-month-old female patient who experienced petechiae and spontaneous ecchymosis. The patient received the first dose on 16-May-2008. The patient also received the first dose of ROTATEQ and the first dose of PEDIARIX (GlaxoSmithKline) on 16-May-2008. Relevant medical history was not provided. Additional suspect vaccines included ROTATEQ, PEDIARIX and ACT-HIB. On 16-May-2008, the patient experienced petechiae and spontaneous ecchymosis and was hospitalized. Laboratory tests were performed (see laboratory results) as sepsis was suspected. No sepsis was found. The patient was hospitalized for 3 days and was discharged and considered recovered. The patient's discharge diagnosis was spontaneous ecchymosis. No additional information was available at the time of this report.
Age: 0.2
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5
Symptoms: Ecchymosis, Haematocrit decreased, Haemoglobin decreased, International normalised ratio normal, Mean platelet volume normal
Clinical narrative: Information regarding PREVENAR was received from a healthcare professional regarding a 2-month-old female patient who experienced petechiae and spontaneous ecchymosis. The patient received the first dose on 16-May-2008. The patient also received the first dose of ROTATEQ and the first dose of PEDIARIX (GlaxoSmithKline) on 16-May-2008. Relevant medical history was not provided. Additional suspect vaccines included ROTATEQ, PEDIARIX and ACT-HIB. On 16-May-2008, the patient experienced petechiae and spontaneous ecchymosis and was hospitalized. Laboratory tests were performed (see laboratory results) as sepsis was suspected. No sepsis was found. The patient was hospitalized for 3 days and was discharged and considered recovered. The patient's discharge diagnosis was spontaneous ecchymosis. No additional information was available at the time of this report.
Age: 0.2
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5, DTAPHEPBIP, HIBV, PNC, RV5
Symptoms: Petechiae, Platelet count decreased, Prothrombin level normal, White blood cell count increased
Clinical narrative: Information regarding PREVENAR was received from a healthcare professional regarding a 2-month-old female patient who experienced petechiae and spontaneous ecchymosis. The patient received the first dose on 16-May-2008. The patient also received the first dose of ROTATEQ and the first dose of PEDIARIX (GlaxoSmithKline) on 16-May-2008. Relevant medical history was not provided. Additional suspect vaccines included ROTATEQ, PEDIARIX and ACT-HIB. On 16-May-2008, the patient experienced petechiae and spontaneous ecchymosis and was hospitalized. Laboratory tests were performed (see laboratory results) as sepsis was suspected. No sepsis was found. The patient was hospitalized for 3 days and was discharged and considered recovered. The patient's discharge diagnosis was spontaneous ecchymosis. No additional information was available at the time of this report.
Age: 65.0
Sex: F
Vaccine: PPV
Symptoms: Pruritus, Skin warm, Swelling
Clinical narrative: Itching, swelling, hot to touch, increasing in size and intensity to 2.5"x4"x1/8" at worst, approximately 36 hours after injection.
Age: 11.0
Sex: F
Vaccine: HPV4, MNQ, HPV4, MNQ
Symptoms: Hypersensitivity, Rash erythematous, Rash pruritic
Clinical narrative: Rash and redness appeared all over the body.
Age: 11.0
Sex: F
Vaccine: HPV4, MNQ, HPV4, MNQ
Symptoms: Erythema, Rash generalised
Clinical narrative: Rash and redness appeared all over the body.
Age: 60.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a 60 year old female with high cholesterol, asthma and a sulfa allergy. The patient reported that she experienced chickenpox as an adult and the virus stays moment in her left ear. At the end of January or beginning of February 2008, the patient was vaccinated with zoster vaccine live (Oka/Merck). Concomitant therapy included atorvastatin calcium (LIPITOR) and levothyroxine Na (SYNTHROID). The patient reported on 22-MAY-2008 that she currently had shingles on her torso. The patient's shingles persisted. The patient sought unspecified medical attention. Additional information has been requested. This is in follow-up to report(s) previously submitted on 6/24/2008.  Information has been received from a 60 year old female with high cholesterol, asthma and a sulfa allergy.  The patient reported that she experienced chickenpox as an adult and the virus stays dorment in her left ear.  At the end of January or beginning of February 2008.  The patient was vaccinated with ZOSTAVAX (Merck).  Concomitant therapy included LIPITOR and SYNTHROID.  The patient reported on 22-MAY-2008 that she currently had shingles on her torso.  The patient's shingles persisted.  The patient sought unspecified medical attention.  Additional information has been requested.
Sex: F
Vaccine: HPV4
Symptoms: Convulsion
Clinical narrative: Information has been received from a mother concerning her daughter who on unspecified dates was vaccinated with 3 doses of GARDASIL.  Subsequently the patient "has been having seizures since she received the three doses of GARDASIL".  The outcome of the seizures was not reported.  It was unspecified if the patient sought medical attention.  No further information is available.
Age: 15.0
Sex: F
Vaccine: HPV4
Symptoms: Grand mal convulsion
Clinical narrative: Information has been received from a physician concerning a 16 year old female with a history of wheezing who on 20-AUG-2007 was vaccinated with her first dose of GARDASIL.  On 22-SEP-2007 the patient experienced tonic clonic seizure and was hospitalized.  On 15-NOV-2007, the patient received the second dose of GARDASIL.  The patient was admitted to the hospital for an unspecified period of time on three separate occasions since the onset of the first seizure.  The patient has a positive familial history of seizures.  The patient's last seizure occurred on an unspecified date in January 2008.  Concomitant therapy included folic acid and MINOCIN.  No other symptoms and no other treatment reported.  Additional information has been requested.  8/11/2008 MR received for multiple DOS 9/22-25/2007, 10/29-11/01/2007, 11/7-12/2007 and ER 1/18/2008 with DX: Epilepsy. Pt presented with 1st seizure 9/22/07. Pt lost consciouness, fell and had generalized convulsion with shaking of upper and lower extremities. Sleepy after. Started on Keppra following EEG. Staring episodes noted with adventitial movements during video. D/C for outpt f/u. Returned again 10/29/07 with 2 episodes of seizure on meds. Recent increase in blinking and decreased attention. Keppra increased. Returned again due to allergic rxn to Keppra.  Med changed to Zonegran. ER visit for seizure in school. Dose increased.
Age: 13.0
Sex: F
Vaccine: HPV4
Symptoms: Convulsion, Dizziness, Electrocardiogram, Loss of consciousness
Clinical narrative: Information has been received from a registered nurse concerning a 13 year old female with a history of reactive airways disease who on 06-FEB-2008 was vaccinated with the first dose of GARDASIL (Lot number 655327/1287U) 0.5 ml, IM. On 27-MAY-2008, the patient received the second dose of GARDASIL (Lot number 655327/1287U). Concomitant therapy included ORTHO TRI-CYCLEN LO. On approximately 03-JUN-2008, 1 week after the second vaccination, the patient experienced seizure. The patient came into the office on 04-JUN-2008 because the patient had several episodes in a 1 week of dizziness and black outs. Unspecified which week this occurred. The patient continues to have seizures. The last seizure was 3 weeks ago. The patient did not have any problems after the first dose of GARDASIL. The patient's seizure persisted. Upon internal service, the seizure was considered to be an other important medical event. Additional information has been requested. 11/05/2008 MR received for DOS 9/11-13/2008 with D/C DX: Seizure-like activity. Pt presented with increasing staring spells x 2 months, where pt is unresponsive. Pt has no recollection of events. Sick to stomach before and very tired after.  Pt dx with Seizure d/o dx June 2008. 12/15/08 Outpt neurology records received with impression ? seizure.
Sex: F
Vaccine: HPV4
Symptoms: Convulsion
Clinical narrative: Information has been received from a physician concerning a female who was vaccinated with a dose of GARDASIL by intramuscular injection in to her arm (lot number not reported). Just as the needle was being pulled out of the patient's arm, the patient experienced seizure.  Unspecified medical attention was sought.  Upon internal review seizure was determined to be an other important medical event.  Additional information has been requested.
Sex: F
Vaccine: HPV4
Symptoms: Paralysis
Clinical narrative: Information has been received from a physician stating that one of his colleagues has received a phone call concerning a female patient who on an unspecified date, was vaccinated with GARDASIL.  Subsequently, the patient was paralyzed after vaccination.  The patient sought for unspecified medical attention.  No additional information is available at this time.  Upon internal review, paralysis was considered to be an other important medical event.  No further information is available.
Age: 15.0
Sex: F
Vaccine: HPV4
Symptoms: Condition aggravated, Convulsion
Clinical narrative: Information has been received from a consumer concerning her 15 year old daughter with seizures and no drug allergies, who on 12-JUN-2008 was vaccinated with a 0.5mL dose of GARDASIL. Concomitant therapy included LAMICTAL. Subsequently, the patient experienced an increase in seizures. No laboratory diagnostics were performed. At the time of the report the patient had not recovered. Upon internal review the seizures were considered to be an other important medical event. Additional information has been requested.
Age: 21.0
Sex: F
Vaccine: HPV4
Symptoms: Drug exposure during pregnancy, Pregnancy test positive
Clinical narrative: Information has been received from the Merck pregnancy registry for GARDASIL from a physician concerning a 21 year old female who on 05-DEC-2007 was vaccinated with her first dose of 0.5 ml GARDASIL (Lot #659437/1266U) intramuscularly and the patient was pregnant. There was no concomitant medication. LMP was 13-NOV-2007 and on 18-DEC-2007 a pregnancy test was performed and results were positive. The physician reported that the patient became pregnant after her first dose of GARDASIL. No other symptoms were reported. Followup phone call information was obtained from a physician who reported that the patient had not continued in his care and may have terminated the pregnancy. No further information was available. Upon internal review elective termination was considered to be an other important medical event. Additional information has been requested.
Age: 16.0
Sex: F
Vaccine: HPV4, HPV4
Symptoms: Pancreatitis, Red blood cell sedimentation rate increased, White blood cell count increased
Clinical narrative: 5 day hospitalization for severe, first-ever pancreatitis. Pt was on Ortho Evra, and had recently - 5/23/08 - completed GARDASIL series. 8/4/08-records received for DOS 7/2-7/7/08- DC DX: Acute pancreatitis possibly secondary to hypertriglyceridemia. Mild iron deficiency anema. Obesity. Protein malnutrition, fevers, elevated inflammatory markers resolving. Dyslipdemia. C/O one day history of severe abdominal pain.
Age: 16.0
Sex: F
Vaccine: HPV4, HPV4
Symptoms: Abdominal pain, Blood amylase, Blood cholesterol increased, Blood triglycerides increased, Computerised tomogram abnormal
Clinical narrative: 5 day hospitalization for severe, first-ever pancreatitis. Pt was on Ortho Evra, and had recently - 5/23/08 - completed GARDASIL series. 8/4/08-records received for DOS 7/2-7/7/08- DC DX: Acute pancreatitis possibly secondary to hypertriglyceridemia. Mild iron deficiency anema. Obesity. Protein malnutrition, fevers, elevated inflammatory markers resolving. Dyslipdemia. C/O one day history of severe abdominal pain.
Age: 16.0
Sex: F
Vaccine: HPV4, HPV4
Symptoms: Dyslipidaemia, Haemoglobin normal, High density lipoprotein increased, Hypertriglyceridaemia, Inflammation
Clinical narrative: 5 day hospitalization for severe, first-ever pancreatitis. Pt was on Ortho Evra, and had recently - 5/23/08 - completed GARDASIL series. 8/4/08-records received for DOS 7/2-7/7/08- DC DX: Acute pancreatitis possibly secondary to hypertriglyceridemia. Mild iron deficiency anema. Obesity. Protein malnutrition, fevers, elevated inflammatory markers resolving. Dyslipdemia. C/O one day history of severe abdominal pain.
Age: 16.0
Sex: F
Vaccine: HPV4, HPV4
Symptoms: Iron deficiency anaemia, Laboratory test normal, Liver function test abnormal, Low density lipoprotein normal, Malnutrition
Clinical narrative: 5 day hospitalization for severe, first-ever pancreatitis. Pt was on Ortho Evra, and had recently - 5/23/08 - completed GARDASIL series. 8/4/08-records received for DOS 7/2-7/7/08- DC DX: Acute pancreatitis possibly secondary to hypertriglyceridemia. Mild iron deficiency anema. Obesity. Protein malnutrition, fevers, elevated inflammatory markers resolving. Dyslipdemia. C/O one day history of severe abdominal pain.
Age: 16.0
Sex: F
Vaccine: HPV4, HPV4
Symptoms: Obesity, Pancreatitis acute, Pyrexia, Red blood cell sedimentation rate increased, Total cholesterol/HDL ratio normal
Clinical narrative: 5 day hospitalization for severe, first-ever pancreatitis. Pt was on Ortho Evra, and had recently - 5/23/08 - completed GARDASIL series. 8/4/08-records received for DOS 7/2-7/7/08- DC DX: Acute pancreatitis possibly secondary to hypertriglyceridemia. Mild iron deficiency anema. Obesity. Protein malnutrition, fevers, elevated inflammatory markers resolving. Dyslipdemia. C/O one day history of severe abdominal pain.
Age: 16.0
Sex: F
Vaccine: HPV4, HPV4
Symptoms: White blood cell count increased
Clinical narrative: 5 day hospitalization for severe, first-ever pancreatitis. Pt was on Ortho Evra, and had recently - 5/23/08 - completed GARDASIL series. 8/4/08-records received for DOS 7/2-7/7/08- DC DX: Acute pancreatitis possibly secondary to hypertriglyceridemia. Mild iron deficiency anema. Obesity. Protein malnutrition, fevers, elevated inflammatory markers resolving. Dyslipdemia. C/O one day history of severe abdominal pain.
Age: 13.0
Sex: F
Vaccine: HPV4
Symptoms: Contusion, Parosmia, Rash
Clinical narrative: Patient reports several areas of bruising and "smell and dots" which resolved after 1 week.
Age: 26.0
Sex: F
Vaccine: HPV4
Symptoms: Hyperhidrosis, Syncope vasovagal
Clinical narrative: Vasovagal reaction, sweats.  Pt. states she didn't have anything to eat.
Age: 33.0
Sex: F
Vaccine: TDAP
Symptoms: Pruritus, Rash pruritic
Clinical narrative: Rash over torso, lasted approximately 36 hours, accompanied by extreme itching on torso
Age: 27.0
Sex: F
Vaccine: TD
Symptoms: Eye swelling, Oedema mouth, Pain in extremity
Clinical narrative: - Immediate arm pain - swelling of mouth and eyes within 8-12 hours - temperature: 98.2 - Benadryl - Return to clinic 1-2 days if not improving
Age: 4.0
Sex: F
Vaccine: DTAP, HEPA, IPV, MMR, VARCEL
Symptoms: Injection site erythema, Injection site swelling
Clinical narrative: 7/11/08 - Client's mom phoned & stated that child had sm. red area on Lt arm (deltoid).  Denies pain - in arm.  Mom brought child to office.  Area on Lt arm was red & about the size of a 50 cent piece.  Mom instructed to call or go see child's MD.  Mom called MD.  He stated to give child ADVIL and to apply warm compress.  7/14/08 - Called mom - she stated area on arm was no longer red or swollen & child was fine.
Age: 12.0
Sex: F
Vaccine: MNQ
Symptoms: Headache, Injection site erythema, Injection site pain, Neck pain
Clinical narrative: Redness soreness around the site, head and neck pain. Treatment- Apply ice alt with heat, ADVIL for pain, call pcp if reaction becomes worse or go to nearest ER.
Age: 2.0
Sex: F
Vaccine: HEPA
Symptoms: Inappropriate schedule of drug administration
Clinical narrative: Hep A pediatric dose given to pt. per order of the physicians assistant.
Age: 0.2
Sex: M
Vaccine: DTAPHEPBIP, HIBV, PNC, RV5
Symptoms: Pallor, Tongue discolouration
Clinical narrative: Per mother report about 630pm on 7/10/08 he turned pale from head to toe and tongue and lips were ashen color. Went to ER and was pale x 1hour then was fine. No fever and has been alert and active on 7/11/08 when mom called office.
Age: 13.0
Sex: M
Vaccine: DTAP, IPV, MMR, VARCEL
Symptoms: Cough, Eye swelling, Ocular hyperaemia, Sneezing
Clinical narrative: Rubbed eyes, red, swollen eyes, sneezing/barky cough.
Age: 21.0
Sex: M
Vaccine: ANTH
Symptoms: Contusion, Erythema, Local reaction, Local swelling, Pain
Clinical narrative: Swollen, bruise, irritation, redness, inflamed, soreness. Pt given MOTRIN for local reaction
Age: 21.0
Sex: M
Vaccine: ANTH
Symptoms: Skin irritation
Clinical narrative: Swollen, bruise, irritation, redness, inflamed, soreness. Pt given MOTRIN for local reaction
Age: 0.5
Sex: M
Vaccine: HEPA
Symptoms: Wrong drug administered
Clinical narrative: None.  Patient given HEP A rather than HEP B #3.
Age: 65.0
Sex: F
Vaccine: VARZOS
Symptoms: Erythema, Injection site erythema, Pyrexia, Skin warm, Urticaria
Clinical narrative: Big red area around the injection site.  The redness is greater below the injection site then above it.  Patient is feverish (100) and area is hot to the touch.
Sex: M
Vaccine: DTAP
Symptoms: Drug administered at inappropriate site, No adverse event
Clinical narrative: DTaP given out of range.
Age: 0.35
Sex: M
Vaccine: HIBV, IPV, PNC, TDAP
Symptoms: Wrong drug administered
Clinical narrative: None.  Tdap given instead of DTaP.
Age: 16.0
Sex: F
Vaccine: HEPA, MNQ
Symptoms: Asthenia, Blood pressure, Cold sweat, Dizziness, Heart rate
Clinical narrative: Patient became light headed, dizzy and weak outside office - very pale and clammy skin. While being brought into physician office, patient became limp and fainted. Received and was talking to staff within 45 secs of fainting episode.